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Edited by Hans EklundAbstract Russells viper venom factor X activator (RVV-X) is a
heterotrimeric metalloproteinase with a mammalian ADAM-like
heavy chain and two lectin-like light chains. The crystal structure
of RVV-X has been determined at 2.9 A˚ resolution and shows a
hook-spanner-wrench-like architecture, in which the metallopro-
teinase/disintegrin region constitutes a hook, and the lectin-like
domains constitute a handle. A 6.5 nm separation between the
catalytic site and a putative exosite suggests a docking model
for factor X. The structure provides a typical example of the
molecular evolution of multi-subunit proteins and insights into
the molecular basis of target recognition and proteolysis by
ADAM/adamalysin/reprolysin proteinases.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Blood coagulation factor X is a serine proteinase and is one
of the key components of the hemostatic system [1]. In circula-
tion, factor X exists as a zymogen and is converted to an active
form, factor Xa, by cleavage of a single peptide bond between
Arg194 and Ile195. This removes the heavily glycosylated ﬁrst
52 amino terminal residues (AP: active peptide) of the heavy
chain, resulting in exposure of the active site. Factor Xa in turn
converts prothrombin to thrombin, which ultimately leads to
formation of hemostatic plugs.
Venom from Russells viper, Daboia russelli, has been recog-
nized for its potent coagulation activity. Russells viper venom
factor X activator (RVV-X) is a well-characterized metallopro-
teinase which speciﬁcally activates factor X by cleaving the
same Arg-Ile bond in factor X that is cleaved by factors IXa
and VIIa during physiological coagulation [2,3]. RVV-X be-
longs to the P-IV class of snake venom metalloproteinases
[4] and consists of a heavy chain of 57,600 Da and two light
chains of 19,400 and 16,400 Da, linked by disulﬁde bonds
[2,5,6]. The 427-residue heavy chain contains the metallopro-Abbreviations: RVV-X, Russells viper venom factor X activator;
ADAM, a disintegrin and metalloproteinase; MDC, metalloprotein-
ase/disintegrin/cysteine-rich; HVR, hyper-variable-region; PEG, poly-
ethyleneglycol
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are shared by the (ADAM) (a disintegrin and metalloprotein-
ase)/adamalysin/reprolysin family proteins. ADAMs are mem-
brane-anchored glycoproteins that can proteolytically release
cell-surface-protein ectodomains, including cell adhesion mol-
ecules, growth factor precursors and their receptors, and have
been associated with numerous diseases including rheumatoid
arthritis, Alzheimers disease, heart disease, and cancer [8,9].
The light chains of RVV-X share amino acid sequence homol-
ogy with mammalian C-type (Ca2+-dependent) lectins and C-
type lectin-like proteins (CLPs) isolated from various snake
venoms [7,10]. RVV-X is one of the best examples of an exog-
enous activators used in coagulation research and has also
been frequently used in diagnostic applications [2]. However,
the molecular mechanism by which RVV-X recognizes and
cleaves factor X is poorly understood, primarily due to the
lack of three-dimensional structural information.
We recently determined the three-dimensional structure of
the metalloproteinase/disintegrin/cysteine-rich (MDC) do-
mains of ADAM/adamalysin/reprolysin family protein VAP1
and suggested a potential protein–protein interaction site that
may function in specifying target proteins [11]. Among the
family proteins, RVV-X is unique in having CLP domains
within the molecule and a strict substrate speciﬁcity. To extend
our understanding of the protein–protein interactions and tar-
get speciﬁcity of this family of proteins, we determined the
crystal structure of RVV-X. Here, we report the crystal struc-
ture of RVV-X at 2.9 A˚ resolution and present a factor X
docking model.2. Materials and methods
RVV-X was purchased from Enzyme Research Laboratories Inc.
and was further puriﬁed using a CM Hi-Trap column (GE healthcare
Bio-Science Corp.) in the presence of GM6001 (N-[(2R)-2-(hydroxam-
idocarbonyllethyl)-4-methylpentanoyl]-L-tryptophan methylamide
(CALBIOCHEM)). Crystals were obtained by the sitting drop vapor
diﬀusion method. Droplets were prepared by mixing 1 ll of protein
solution and 1 ll of reservoir solution (0.1 M calcium acetate, 0.1 M
sodium cacodylate, 10% PEG8000, pH 6.5) supplemented with one
ﬁfth volume of 10% PEG3350 and were equilibrated against 1 ml of
reservoir solution at 293 K, typically for one week. Crystals were
soaked in reservoir solution supplemented with 15% MPD (2-
methyl-2,4-pentandiol) prior to ﬂash cryo-cooling under a stream of
nitrogen gas at 100 K.
The diﬀraction data set was acquired using the SPring-8 beamline
BL41XU at a wavelength of 1.0 A˚ at 100 K. The best crystal generated
a data set with a 2.9 A˚ resolution (Table 1). The asymmetric unit con-
tained one RVV-X molecule. The RVV-X structure was solved by the
molecular replacement method using search models constructed from
acutolysin-C (1QUA), catrocollastatin/VAP2B (2DW0), and fIX-bind-blished by Elsevier B.V. All rights reserved.
Table 1





a, b, c (A˚) 70.4, 91.7, 152.9
a, b, c () 90, 90, 90




Completeness (%) 96.4 (79.5)
Redundancy 6.3 (5.5)
Reﬁnement
Resolution (A˚) 44.6–2.91 (3.0–2.91)











Bond lengths (A˚) 0.0045
Bond angles () 1.12









iIi(hkl), where Ii(hkl) is the
ith intensity measurement of reﬂection hkl and ÆI(hlk)æ is its average.
bRwork =
P
(i Fobsj  jFcalci)/
PjFobsj.
cRfree = R-value for a randomly selected subset (5%) of the data that
were not used for minimization of the crystallographic residual.
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The ﬁnal model includes amino acid residues 7-422 of the heavy chain,
1-59 and 64-133 of light chain-A (LA) and 3-123 of light chain-B (LB),
and was reﬁned to a resolution of 2.9 A˚ (Table 1). The overall resolu-
tion is not particularly high when compared to those of the other snake
venom protein structures, most likely due to the relatively high solvent
content of the crystal (60%) and the ﬂexible modular architecture of
the MDC domains [12]. However, well-determined structural models
for most sub-domains generated the electron-density maps that enable
us to build a reliable model. The overall B-factor is relatively high
(average B-factor of the total protein atoms is 72.2 A˚2) and the elec-
tron-densities associated with the charged side-chains located on the
molecular surface (61 aa corresponding to 9% of the total model of
672 aa) are not clearly observed, however, almost all of the side-chains
inside the molecule are deﬁned in the ﬁnal electron-density maps
(Fig. 1B and C). Details of preparation, crystallization and structural
analysis are described in the Supplementary information.3. Results and discussion
3.1. Overall structure of RVV-X
The overall structure of RVV-X resembles a hook-spanner-
wrench conﬁguration, where the major portion of the heavy
chain forms a hook and the remaining heavy chain portion
and the light chains form a handle (Fig. 1A). The backbone
structure of the heavy chain is essentially the same as each
monomer of VAP1 [11] and catrocollastain/VAP2B [12], with
the exception of the sub-domain orientations (Fig. 1D and
E). There are direct, but less-speciﬁc interactions between the
M and C domains, most likely resulting from crystal packing
forces, such that the entire RVV-X MDC domain forms a
closed C-shape structure, unlike the open C-shaped structures
of VAP1 and catrocollastain/VAP2B. The M domain of RVV-
X has a ﬂat elliptical shape with a core formed by a ﬁve-stranded b-sheet and ﬁve a-helices and contains the conserved
Zn2+-binding HEXXHXXGXXHD sequence (residues 145–
156) and a ‘‘Met-tern’’ (Met169) bearing the typical structural
features of the metzincin family of metalloproteinases [13].
RVV-X has a fourth disulﬁde bridge (Cys27-Cys63)
(Fig. 1B), in addition to the three conserved disulﬁde bridges
(Cys120-Cys200, Cys160-Cys184 and Cys162-Cys167) [4] in
the M domain. The M domain is followed by the D and C do-
mains, which are further divided into shoulder (Ds), arm (Da),
wrist (Cw) and hand (Ch), segments, and the entire heavy chain
folds into a C-shaped structure (Fig. 1A). The heavy chain
contains three structural Ca2+-binding sites and a number of
disulﬁde bridges (9 and 5 in the D and C domains, respectively)
that are highly conserved among the ADAM/adamalysin/repr-
olysin family proteins [11,12].
The two homologous light chains have a fold similar to the
carbohydrate-recognition domain (CRD) of rat mannose bind-
ing protein (MBP) [14], but they form an intertwined dimer
where the central portion of each chain projects toward the
adjoining subunit (Fig. 1A). The light chains are related by a
pseudo 2-fold axis which is perpendicular to the long axis of
the light chain dimer.3.2. (HVR)-mediated protein–protein interaction
RVV-X has a unique cysteine residue (Cys389) in the middle
of the hyper-variable-region (HVR, residues 373–394) in Ch, a
putative protein–protein interaction site for this family of pro-
teins [11]. Cys389 forms a disulﬁde bond with the C-terminal
cysteine residue (Cys133) of LA (Fig. 1A and C). Aside from
this inter-chain disulﬁde bridge, Tyr346, Tyr347, and Met385
in the heavy chain form multiple hydrophobic interactions
and hydrogen bonds with Tyr11, Phe12, and Pro131 in LA,
which further stabilize the continuous Ch/LA structure
(Fig. 1C). Most of these residues involved in the interaction be-
tween Ch and LA are not conserved among ADAMs [11,12] or
among other CLPs [10]. The RVV-X structure represents the
ﬁrst example of HVR-mediated protein–protein interactions
by the ADAM/adamalysin/reprolysin family proteins.3.3. Light chains
Both the overall structure and the surface features of the
RVV-X light chains are quite similar to those of the factor
X-binding protein (X-bp) from Deinagkistrodon actus venom
(the r.m.s. deviation of the 240 equivalent Ca atoms is 2.6 A˚)
determined in complex with the c-carboxyglutamic acid
(Gla) domain of factor X [15] (Fig. 2A and B). X-bp has strong
anticoagulant activities because it binds to the Gla domain of
factor X and inhibits its membrane-anchoring function [16].
The hydrophobic residues that are critical for the membrane-
anchoring function of factor X (Phe4, Leu5 and Val8) interact
with the hydrophobic patch formed by the hydrophobic resi-
dues (Met113, Ile114 and Ala115) of the B chain in X-bp
[15]. Those residues are conserved in RVV-X (Phe114, Ile115
and Ala116 of LB) (Fig. 2B). The positively charged patches
on X-bp that directly interact with the Gla residues in factor
X are conserved, but, are less prominent in RVV-X because
of amino acid substitutions (especially, Ile101 and Glu104)
(Fig. 2B). The structural similarities between the RVV-X light
chains and X-bp suggest the intriguing possibility that RVV-X
recognizes the factor X Gla domain through an exosite,
formed by the light chains (Fig. 2C).
Fig. 1. Structure of RVV-X. (A) Ribbon structure of RVV-X in stereo. Bound calcium and zinc ions are represented by black and red spheres,
respectively. The carbohydrate moieties (in green) linked to asparagine residues and GM6001 (in magenta) are shown in ball-and-stick
representations. 2Fo  Fc electron-density maps (1.0r) around the disulﬁde bridge between Cys27(HC) and Cys63(HC), and between Cys389 (HC)
and Cys133 (LA) are represented in (B) and in (C), respectively. The HC and LA residues are labelled in black and in red, respectively. (D)
Superimposition of the Ch segment of the RVV-X heavy chain (in pink) with that of the VAP1 monomer (chain-A in 2ERO, in yellow), and with that
of the catrocollastatin/VAP2B (chain-A in 2DW0, in cyan) in stereo. The bound zinc and calcium atoms in RVV-X are shown as red and black
spheres, respectively. The zinc atoms in VAP1 and catrocollastain/VAP2B are shown as green and blue spheres, respectively. (E) Superimposition of
the M domain of the RVV-X heavy chain with the M domains of the VAP1 monomer and catrocollastatin/VAP2B.
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the rate of factor X activation by RVV-X is markedly dimin-
ished. In the acarboxy factor X, in which Gla formation has
been blocked by a vitamin K antagonist [17] or the Des (1-44)
factor X [18], factor X activation occurs at less than 1% of the
rate of native factor X. Activation of factor X by RVV-X is dra-matically enhanced bymillimolar Ca2+, which induces a confor-
mational change in the Gla domain that enhances its binding to
RVV-X [19].Moreover, RVV-X catalyzed factor X activation is
inhibited by X-bp [7]. Collectively, these observations suggest
that the concave cleft created between the two light chains in
RVV-X may function as an exosite for factor X-binding.
Fig. 2. Comparison of the RVV-X light chains and X-bp. (A)
Superimposition of the RVV-X light chains (LA in orange and LB
in magenta) onto the structure of X-bp (in gray) in complex with the
Gla domain (in pink) of factor Xa (1IOD). The Gla residues and the
Ca2+ ions are shown in ball-and-stick representation and as green
spheres, respectively. (B) The molecular surfaces of X-bp and the light
chains of RVV-X are represented according their electrochemical
potentials (blue for positive, red for negative) and are viewed from the
pseudo 2-fold axis. Conserved and varied residues are labelled in cyan
and in red, respectively. (C) A model of the RVV-X light chains in
complex with the Gla domain that was positioned based on the X-bp/
fX Gla domain complex structure.
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Fig. 3A represents a preliminary docking model. For con-
structing a model, ﬁrstly, the second EGF domain (EGF2)
and the serine proteinase (SP) domain of factor Xa
(PDBID:1XKA) were placed such that the N-terminus of the
factor X heavy chain (Ile195) closely approaches the RVV-X
























































Fig. 3. Docking model. (A) The surfaces of the RVV-X sub-domains
are coloured as in Fig. 1A. Factor Xa is shown in ribbon represen-
tation. Ile195 (in stick representation) and the N-terminal region
(residues 195-201) of the factor X heavy chain are shown in magenta.
In the right panel, the EGF1 segment of the original structural model
(1XKA) is shown in gray. (B) Close up view of the RVV-X catalytic
site of the docking model viewed from inside the factor Xa molecule.
The N-terminal residues of factor Xa are shown in white and those of
the model of factor X (zymogen) are shown in light pink. Because the
factor X structure is currently unavailable, we assumed that this region
has an extended structure. (C) Schematic model of factor X activation
by RVV-X.
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duced a 50 bend between the two EGF domains so that the
EGF1 domain ﬁts to the convex surface of the LA domain
(Fig. 3A). The linker between the two EGF domains is most
likely ﬂexible in solution [20]. This displacement successfully
placed the N-terminus of the EGF1 domain in close proximity
to the C-terminus of the Gla domain.
In the factor Xa structure, the N-terminal residue of the hea-
vy chain, Ile195, is buried within the protein [20]. However, in
the zymogen, the intact Arg194-Ile195-containing segment
must be situated on the molecular surface, as in the equivalent
segments of other serine proteinase zymogen structures [21].
The region of factor X that is C-terminal to the scissile peptide
(segment coloured in magenta in Fig. 3A) may be located
along the surface of the SP domain, resulting in its binding
to the primed region of RVV-X, in the same orientation as
the peptide-like inhibitor GM6001 lies in the current crystal
structure (Fig. 3B). In the present docking model, since both
molecules were positioned just as a rigid body without any col-
lision, the active site zinc atom of RVV-X and Ile195 of factor
Xa are 16 A˚ apart. Intrinsic hinge motions of the modular M/
Ds/Da/Cw architecture [12], and conformational changes upon
association of RVV-X and the factor X zymogen, may allow
the catalytic site of RVV-X to interact directly with the
Arg194-Ile195 bond of factor X when in solution (Fig. 3C).
The relatively large separation (65 A˚) of the catalytic site
and the Gla-domain-binding exosite may explain the high
speciﬁcity of RVV-X for factor X.3.5. Implication for molecular evolution of RVV-X
CLPs from snake venoms are characterized by a unique
dimerization mechanism of protein evolution, in which two
monomers swap a portion of the long loop region, forming a
stable functional unit and creating a new concave surface for
target binding for a variety of biological activities [10]. Dimers
can further aggregate with each other to form higher-order
oligomers [22], or, as in the case of RVV-X, form covalently
linked complexes with a metalloproteinase chain creating an
exosite. The RVV-X structure illustrates a good example of
evolutionary gain of function by multi-subunit proteins, repre-
sented by the fold adaptation, for the binding of other ligands.4. Conclusion
ADAMs are widely distributed and constitute the major
membrane-bound sheddases to play roles in important pro-
cesses occurring at the cell surface. However, the molecular
mechanism of target recognition by ADAMs and which
ADAMs shed which key substrates in speciﬁc biological events
has been poorly understood. Previously, we suggested that the
HVR may constitute an exosite that captures the target or
associated proteins, and that is processed by the catalytic site
[11]. The RVV-X structure is consistent with this model and
provides insights into the molecular basis of HVR-mediated
protein–protein interactions and target recognition by
ADAM/adamalysin/reprolysin family proteins.
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